<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:department>Immunity and Infection</gtr:department><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/42BD86F1-9CB8-42B2-9ED3-F55CBC6ECAB1"><gtr:id>42BD86F1-9CB8-42B2-9ED3-F55CBC6ECAB1</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Simmons</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/16B653E2-0DEA-4EC3-BEB0-B755754726BD"><gtr:id>16B653E2-0DEA-4EC3-BEB0-B755754726BD</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:surname>Buckley</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/F2C9D75C-2BAC-4470-B9D7-445E2472DCA4"><gtr:id>F2C9D75C-2BAC-4470-B9D7-445E2472DCA4</gtr:id><gtr:firstName>Karim</gtr:firstName><gtr:surname>Raza</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0800754"><gtr:id>0691A771-02E0-4F37-A260-B838806C079F</gtr:id><gtr:title>Profiling the expressed kinome in patients with early rheumatoid arthritis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0800754</gtr:grantReference><gtr:abstractText>Rheumatoid arthritis affects 1-2% of the UK population and is a chronic debiltating disease with high cost to society. Disease modifying drugs, particularly biological therapies, have had a beneficial clinical and health impact on patients. However, there is a need to discover and develop both more clinically and cost effective treatment options. The study propsoed will allow direct analysis of the targets of new classes of DMARDs in relevant human ex vivo systems to allow more informed clinical development.</gtr:abstractText><gtr:technicalSummary>Defining robust and reliable predictors of disease outcome in patients at their time of presentation with an inflammatory arthritis remains an elusive goal. Currently the best predictor of disease persistence is time (ie disease duration 3 months). This issue is particularly relevant as there is now emerging evidence that disease specific damage to synovial joints occurs early in Rheumatoid Arthritis (RA) and that early intervention with disease modifying drugs (including biological agents such as the anti TNF-?? agents, infliximab and etanercept), slow the rate of joint damage. We have identified a unique and transient synovial fluid cytokine profile from patients with very early inflammatory synovitis that predicts the subsequent development of rheumatoid arthritis and defines a pathologically unique window for early therapy in inflammatory arthritis destined to become RA. 

As this cytokine portrait includes both T cell and fibroblast derived cytokines we now propose to define the profile of expressed kinases in peripheral blood T cells and synovial fibroblasts in patients who present with early inflammatory arthritis in order to assign a core kinome signature (CKS) to patients whose synovitis resolves (good outcome disease) versus those who develop RA (bad outcome disease). 

We predict that, patients with early inflammatory arthritis destined to become RA will have a CKS that includes T cell and fibroblast restricted kinases that can predict outcome. If this is the case it will provide a clear rationale and help target the nature of therapy in patients with very early synovitis.</gtr:technicalSummary><gtr:fund><gtr:end>2010-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>167474</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Cellzome Ltd</gtr:department><gtr:description>BEAT-RA Experimental Arthritis Center</gtr:description><gtr:id>AAA41C90-63DB-46BA-8EDC-D5C9AF6BBFF2</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>mhXqBdyL4YP-1</gtr:outcomeId><gtr:piContribution>Collaboation with CellZome to investiagte early Phase2a studies</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Cellzome Ltd</gtr:department><gtr:description>CellZome</gtr:description><gtr:id>7593E6D2-7369-4C3E-9AFD-5B898E83A8FB</gtr:id><gtr:impact>This collaboration led to an MRC Industrial partnership grnat G0800754</gtr:impact><gtr:outcomeId>BFB796486E7-1</gtr:outcomeId><gtr:partnerContribution>Reagents</gtr:partnerContribution><gtr:piContribution>Provision of samples for kinase assays</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Glasgow</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ARUK CoE in RA Pathogenesis</gtr:description><gtr:id>8246E531-34A1-4363-81B6-00B0431EA471</gtr:id><gtr:impact>Just started</gtr:impact><gtr:outcomeId>pacjC9v93fy-1</gtr:outcomeId><gtr:partnerContribution>As above</gtr:partnerContribution><gtr:piContribution>ARUK Center of Excellence in te pathogenesis of RA</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ARUK CoE in RA Pathogenesis</gtr:description><gtr:id>38BA88AC-8807-4F14-A4EE-372386E34042</gtr:id><gtr:impact>Just started</gtr:impact><gtr:outcomeId>pacjC9v93fy-2</gtr:outcomeId><gtr:partnerContribution>As above</gtr:partnerContribution><gtr:piContribution>ARUK Center of Excellence in te pathogenesis of RA</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>6000000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>EU FP7</gtr:description><gtr:end>2016-10-02</gtr:end><gtr:fundingOrg>European Research Council (ERC)</gtr:fundingOrg><gtr:id>5E805FCE-8D05-4D1C-9F84-6E88BA30F1CD</gtr:id><gtr:outcomeId>cxCpkfqJed2</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>National Audit Office</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3721DBE1-B463-4D55-8AD0-888B31562C42</gtr:id><gtr:outcomeId>338E4575461</gtr:outcomeId><gtr:type>Citation in other policy documents</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>33DBA519-6CAB-4688-8812-799A8A3C0BB7</gtr:id><gtr:title>Galectin 3 induces a distinctive pattern of cytokine and chemokine production in rheumatoid synovial fibroblasts via selective signaling pathways.</gtr:title><gtr:parentPublicationTitle>Arthritis and rheumatism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a76a305e99311abb6cb889145b2c5d8"><gtr:id>1a76a305e99311abb6cb889145b2c5d8</gtr:id><gtr:otherNames>Filer A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0004-3591</gtr:issn><gtr:outcomeId>229215C9468</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3CE2FB42-26A4-4A55-AF2D-1174EBB41499</gtr:id><gtr:title>Stromal cells differentially regulate neutrophil and lymphocyte recruitment through the endothelium.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db514f3de5ae34ad737a2d976461bbff"><gtr:id>db514f3de5ae34ad737a2d976461bbff</gtr:id><gtr:otherNames>McGettrick HM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn><gtr:outcomeId>XHaerY9Dhhx</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6E5FA3C0-1AB8-43F4-A8F8-985EC780529E</gtr:id><gtr:title>Altered expression of microRNA-203 in rheumatoid arthritis synovial fibroblasts and its role in fibroblast activation.</gtr:title><gtr:parentPublicationTitle>Arthritis and rheumatism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/763c819ffc32bce8b5e1c8b676d49c29"><gtr:id>763c819ffc32bce8b5e1c8b676d49c29</gtr:id><gtr:otherNames>Stanczyk J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0004-3591</gtr:issn><gtr:outcomeId>UpsmuEzhvW8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>178B8B80-87D6-481C-85FD-7B4215584136</gtr:id><gtr:title>Why does chronic inflammation persist: An unexpected role for fibroblasts.</gtr:title><gtr:parentPublicationTitle>Immunology letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a96b012457623cf527842060642b7ad3"><gtr:id>a96b012457623cf527842060642b7ad3</gtr:id><gtr:otherNames>Buckley CD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0165-2478</gtr:issn><gtr:outcomeId>jNczmAggzeJ</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800754</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>